State of New Jersey Common Pension Fund D Cuts Stock Position in Kenvue Inc. $KVUE

State of New Jersey Common Pension Fund D trimmed its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 649,502 shares of the company’s stock after selling 1,826 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Kenvue were worth $13,594,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Kenvue by 4.9% during the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock worth $5,494,882,000 after purchasing an additional 10,600,682 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Kenvue by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock worth $613,882,000 after purchasing an additional 633,461 shares in the last quarter. Boston Partners increased its position in shares of Kenvue by 7.4% during the first quarter. Boston Partners now owns 25,346,453 shares of the company’s stock worth $606,920,000 after purchasing an additional 1,750,490 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Kenvue by 11.6% during the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock worth $597,395,000 after purchasing an additional 2,597,920 shares in the last quarter. Finally, American Century Companies Inc. increased its position in shares of Kenvue by 15.7% during the first quarter. American Century Companies Inc. now owns 21,828,854 shares of the company’s stock worth $523,456,000 after purchasing an additional 2,961,716 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Down 0.6%

NYSE:KVUE opened at $15.00 on Friday. The stock’s 50 day moving average price is $17.91 and its 200 day moving average price is $20.79. The company has a market capitalization of $28.78 billion, a PE ratio of 20.26, a P/E/G ratio of 2.16 and a beta of 0.72. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52-week low of $14.05 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 5.5%. The ex-dividend date of this dividend was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 112.16%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of recent research reports. Rothschild Redb raised Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, September 26th. Canaccord Genuity Group lowered their price objective on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Bank of America lowered their price objective on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Wednesday, October 8th. UBS Group decreased their target price on Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 8th. Finally, Citigroup reduced their price target on Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.